Innovent Biologics to Release 2.08 Million Restricted Shares for Trading on July 18

Market Watcher

2025/07/15

Innovent Biologics (688428/09969) announced on July 15 details regarding the vesting outcomes of its 2023 STAR Market restricted stock incentive plan. The second vesting period for initially granted shares and the first vesting period for reserved shares will result in 2.08 million A-shares becoming tradable on July 18, 2025.

According to the disclosure, Innovent Biologics reported robust first-quarter 2025 financial performance, achieving revenue of 381 million yuan with net profit attributable to shareholders reaching 17.97 million yuan. This share release marks a significant milestone in the company's equity incentive program execution.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1150931812"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1150931812\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1150931812?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-15 20:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1150931812","market":"us","top_or_hot":-1,"title":"Innovent Biologics to Release 2.08 Million Restricted Shares for Trading on July 18","media":"Market Watcher","content":"<p>Innovent Biologics (688428/09969) announced on July 15 details regarding the vesting outcomes of its 2023 STAR Market restricted stock incentive plan. The second vesting period for initially granted shares and the first vesting period for reserved shares will result in 2.08 million A-shares becoming tradable on July 18, 2025.</p>\n<p>According to the disclosure, Innovent Biologics reported robust first-quarter 2025 financial performance, achieving revenue of 381 million yuan with net profit attributable to shareholders reaching 17.97 million yuan. This share release marks a significant milestone in the company's equity incentive program execution.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Innovent Biologics to Release 2.08 Million Restricted Shares for Trading on July 18</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInnovent Biologics to Release 2.08 Million Restricted Shares for Trading on July 18\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Market Watcher</strong><span class=\"h-time small\">2025-07-15 20:54</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Innovent Biologics (688428/09969) announced on July 15 details regarding the vesting outcomes of its 2023 STAR Market restricted stock incentive plan. The second vesting period for initially granted shares and the first vesting period for reserved shares will result in 2.08 million A-shares becoming tradable on July 18, 2025.</p>\n<p>According to the disclosure, Innovent Biologics reported robust first-quarter 2025 financial performance, achieving revenue of 381 million yuan with net profit attributable to shareholders reaching 17.97 million yuan. This share release marks a significant milestone in the company's equity incentive program execution.</p>\n<div class=\"bt-text\">\n\n\n<p> 來源：<span>Market Watcher</span></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1150931812","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1150931812","pubTimestamp":1752584072,"columns":[],"sourceInfo":null,"weMediaInfo":null,"summary":"Innovent Biologics (688428/09969) announced on July 15 details regarding the vesting outcomes of its 2023 STAR Market restricted stock incentive plan. The second vesting period for initially granted...","collect":0,"end_time":0,"defaultTopTitle":"laohu8.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"688428":"诺诚健华","BK1161":"生物科技","BK1574":"生物医药B类股","09969":"诺诚健华","BK0239":"医药制造"},"translate_title":"信达生物将于7月18日解除限售股208万股","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688428":1,"09969":1},"content_text":"Innovent Biologics (688428/09969) announced on July 15 details regarding the vesting outcomes of its 2023 STAR Market restricted stock incentive plan. The second vesting period for initially granted shares and the first vesting period for reserved shares will result in 2.08 million A-shares becoming tradable on July 18, 2025.\nAccording to the disclosure, Innovent Biologics reported robust first-quarter 2025 financial performance, achieving revenue of 381 million yuan with net profit attributable to shareholders reaching 17.97 million yuan. This share release marks a significant milestone in the company's equity incentive program execution.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}